Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence

The recurrence of glioma is a difficult problem in clinical treatment. The molecular markers of primary tumors after resection cannot fully represent the characteristics of recurrent tumors. Here, abundant tumor DNA was detected in tumor in situ fluid (TISF). We report that TISF-derived tumor DNA (T...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 742037
Main Authors Yu, Jinliang, Sheng, Zhiyuan, Wu, Shuang, Gao, Yushuai, Yan, Zhaoyue, Bu, Chaojie, Gu, Jianjun, Bu, Yage, Deng, Kaiyuan, Xu, Sensen, Chen, Zhongcan, Zhang, Qianqian, Zemmar, Ajmal, Hernesniemi, Juha, Wang, Meiyun, Liu, Gang, Li, Tianxiao, Bu, Xingyao
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 11.10.2021
Subjects
circulating tumor DNA
glioma progression
Oncology
precision medicine
spatiotemporal heterogeneity
tumor in-situ fluid
Online AccessGet full text

Cover

More Information
Summary:The recurrence of glioma is a difficult problem in clinical treatment. The molecular markers of primary tumors after resection cannot fully represent the characteristics of recurrent tumors. Here, abundant tumor DNA was detected in tumor in situ fluid (TISF). We report that TISF-derived tumor DNA (TISF-DNA) can detect genomic changes in recurrent tumors and facilitate recurrence risk analysis, providing valuable information for diagnosis and prognosis. The tumor DNA in TISF is more representative and sensitive than that in cerebrospinal fluid. It reveals the mutational landscape of minimal residual disease after glioma surgery and the risk of early recurrence, contributing to the clinical management and clinical research of glioma patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors share senior authorship
Edited by: Khan Iftekharuddin, Old Dominion University, United States
These authors have contributed equally to this work
Reviewed by: Giselle Lopez, Duke University, United States; Ayca Erşen Danyeli, Associate Professor, İstanbul, Turkey
This article was submitted to Neuro-Oncology and Neurosurgical Oncology, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.742037